Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Candidate Pathways, Whole Genome Scans
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Cancer Research 66, 9913-9920, October 15, 2006. doi: 10.1158/0008-5472.CAN-06-0377
© 2006 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitsui, Y.
Right arrow Articles by Okada, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitsui, Y.
Right arrow Articles by Okada, Y.

Cell, Tumor, and Stem Cell Biology

ADAM28 Is Overexpressed in Human Breast Carcinomas: Implications for Carcinoma Cell Proliferation through Cleavage of Insulin-like Growth Factor Binding Protein-3

Yoko Mitsui1,2, Satsuki Mochizuki1, Takahide Kodama1, Masayuki Shimoda1, Takashi Ohtsuka1, Takayuki Shiomi1, Miyuki Chijiiwa1, Tadashi Ikeda2, Masaki Kitajima2 and Yasunori Okada1

Departments of 1 Pathology and 2 Surgery, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan

Requests for reprints: Yasunori Okada, Department of Pathology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku Tokyo 160-0016, Japan. Phone: 81-3-5363-3763; Fax: 81-3-3353-3290; E-mail: okada{at}sc.itc.keio.ac.jp.

A disintegrin and metalloproteinases (ADAMs) are involved in various biological events including cell adhesion, cell fusion, membrane protein shedding, and proteolysis. In the present study, our reverse transcription-PCR analysis showed that among the 12 different ADAM species with a putative metalloproteinase motif, prototype membrane-anchored ADAM28m and secreted-type ADAM28s are selectively expressed in human breast carcinoma tissues. By real-time quantitative PCR, their expression levels were significantly higher in carcinomas than in nonneoplastic breast tissues. In situ hybridization, immunohistochemistry, and immunoblotting analyses indicated that ADAM28 is predominantly expressed in an active form by carcinoma cells within carcinoma tissues. A direct correlation was observed between mRNA expression levels and proliferative activity of the carcinoma cells. Treatment of ADAM28-expressing breast carcinoma cells (MDA-MB231) with insulin-like growth factor-I (IGF-I) increased cell proliferation, cleavage of IGF binding protein (IGFBP)-3, as well as IGF-I cell signaling; these processes were all significantly inhibited by treatment with ADAM inhibitor or anti-ADAM28 antibody. Down-regulation of ADAM28 expression in MDA-MB231 cells with small interfering RNA significantly reduced cell proliferation, IGFBP-3 cleavage, and growth of xenografts in mice. In addition, cleavage of IGFBP-3 in breast carcinoma tissues was correlated with ADAM28 expression levels and inhibited by treatment with ADAM inhibitor or anti-ADAM28 antibody. These results show that ADAM28 is overexpressed in an activated form in human breast carcinoma cells and suggest that ADAM28 is involved in cell proliferation through enhanced bioavailability of IGF-I released from the IGF-I/IGFBP-3 complex by selective IGFBP-3 cleavage in human breast carcinomas. (Cancer Res 2006; 66(20): 9913-20)




This article has been cited by other articles:


Home page
BloodHome page
I. Hers
Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3K{alpha} pathway
Blood, December 15, 2007; 110(13): 4243 - 4252.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Shimoda, G. Hashimoto, S. Mochizuki, E. Ikeda, N. Nagai, S. Ishida, and Y. Okada
Binding of ADAM28 to P-selectin Glycoprotein Ligand-1 Enhances P-selectin-mediated Leukocyte Adhesion to Endothelial Cells
J. Biol. Chem., August 31, 2007; 282(35): 25864 - 25874.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2006 by the American Association for Cancer Research.